DxGen is global Point-Of-Care(POC) diagnostics company. Our goal is to help make clinical decisions in the care and treatment of patients at the time and place. We are committed to applying leading-edge technology for high-quality products. We endeavor to be a global leader and deliver technical innovation continuously.
DxGen devoted to developing multi-marker for people with diabetes and tuberculosis. We provide total solution and offers tools and services to help developing POC products from concept through commercialization. Healthcare professionals will have reliable test results in minutes with the lab quality precision and accuracy while operating cost effectively.
Founders and leadership of the company are an experienced team composed of industry leaders with successful track records. A powerful combined team with strong R&D capabilities and experience is what truly drives innovation. We are building a global investor, strategic partner and customer base and plan to manufacture components in multiple locations worldwide.
Board of Directors
Dr. Jinwoo Lee is famous entrepreneur and has set out to pioneer In-Vitro Diagnostics (IVD) fields approach to global market by inventing Blood Glucose Monitoring System (BGMS), HbA1c, Hemoglobin meter and Point-of-care (POC) diagnostics systems.
Prof. Tae Jung Park received his Ph.D. degree at the Department of Chemical & Biomolecular Engineering of KAIST in 2004. He has been a professor at the Chemistry department of Chung-Ang University.
Hyukjun Oh received the B.S., M.S., and Ph.D. degrees from the Korea Advanced Institute of Science and Technology (KAIST), in 1993, 1995, and 1999, respectively.
Prof.Sung Tack Chung received his Ph.D. degree at the Department of Electronic Engineering of KAIST. He has been a professor at the Computer Science department of Korea Poly-technic University from 2004.